OTCMKTS:IMUN Immune Therapeutics (IMUN) Stock Price, News & Analysis $0.09 0.00 (0.00%) As of 10/19/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Immune Therapeutics Stock (OTCMKTS:IMUN) Get Immune Therapeutics alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.07▼$1.30Volume12 shsAverage Volume15,246 shsMarket Capitalization$7.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida. Read More Receive IMUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMUN Stock News HeadlinesImmune Checkpoint Inhibitors Market Report 2026-2030 with Detailed Company Profiles, Grant Analyses, Partnership Evaluations and MoreApril 21, 2026 | finance.yahoo.comMindImmune Secures $5 Million Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Pioneer Immune-Driven Therapies for Alzheimer’s DiseaseMarch 10, 2026 | finance.yahoo.comWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores unmarried partners, unequal financial needs among heirs, and charities you supported. Outdated beneficiary forms on retirement accounts can send assets to ex-spouses or estranged relatives, regardless of what your will says. Probate without a will can take months or years, freeze your assets, and become part of the public court record. A fiduciary financial advisor can walk you through beneficiary designations, trust structures, and tax strategy before it's too late.July 2 at 1:00 AM | SmartAsset (Ad)AC Immune Initiates Phase 1 Clinical Trial of NLRP3 InhibitorFebruary 24, 2026 | markets.businessinsider.comAdvancing Solid Tumor Immunotherapy: Primmune Therapeutics Raises $8.6MFebruary 23, 2026 | latimes.comImmune Cells Do Something Unexpected to Stop This Brain Parasite From SpreadingFebruary 18, 2026 | msn.comBuying Guide-Best Mushroom Gummies of 2026 for Immune Support, Energy Boost & Stress Relief lineup MushcanyonFebruary 17, 2026 | finance.yahoo.comImmune Checkpoint Inhibitor Therapy May Reduce Asthma ExacerbationsFebruary 16, 2026 | finance.yahoo.comSee More Headlines IMUN Stock Analysis - Frequently Asked Questions How have IMUN shares performed this year? Immune Therapeutics' stock was trading at $0.0930 on January 1st, 2026. Since then, IMUN stock has increased by 0.0% and is now trading at $0.0930. How do I buy shares of Immune Therapeutics? Shares of IMUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Therapeutics investors own include Asia Broadband (AABB), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Northwest Biotherapeutics (NWBO), Galiano Gold (AKG) and Agritek (AGTK). Company Calendar Today7/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IMUN CIK1559356 Webwww.immunetherapeutics.com Phone(888) 613-8802FaxN/AEmployees2Year Founded2012Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.54 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-544.75% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-3.10Miscellaneous Outstanding Shares83,660,000Free Float41,335,000Market Cap$7.78 million OptionableNot Optionable Beta0.46 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:IMUN) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredGreatest Hedge Fund Manager of All Time: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a histo...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
